Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1994; 23:652-657
© 1994 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaski, J.
Right arrow Articles by Chen, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaski, J.
Right arrow Articles by Chen, L

Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina

JC Kaski, G Rosano, S Gavrielides, and L Chen

Department of Cardiological Sciences, St. George's Hospital Medical School, London, England, United Kingdom.

OBJECTIVES. This study was conducted to test the hypothesis that angiotensin-converting enzyme inhibition may lessen myocardial ischemia in patients with microvascular angina. BACKGROUND. Patients with syndrome X (angina pectoris, positive findings on exercise testing and normal coronary arteriogram) have a reduced coronary vasodilator reserve ("microvascular angina") and may show an increased sympathetic drive. Angiotensin-converting enzyme inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. METHODS. Ten patients (seven women and three men, mean age [+/- SD] 53 +/- 6 years) with syndrome X and a reduced coronary flow reserve underwent a randomized, single-blind, crossover, placebo-controlled study of the effects of the angiotensin-converting enzyme inhibitor enalapril on angina and exercise-induced ST segment depression. Assessment was by symptom-limited treadmill exercise testing after 2 weeks of treatment with 10 mg/day of enalapril and after 2 weeks of placebo administration. RESULTS. All patients had positive findings on exercise testing (> or = 1 mm ST segment depression and angina) while taking placebo, whereas six patients had a positive test result (four with angina) during enalapril therapy. Total exercise duration and time to 1 mm of ST segment depression were prolonged by enalapril over those obtained with placebo (mean 779 +/- 141 vs. 690 +/- 148 s, p = 0.006 and 690 +/- 204 vs. 485 +/- 241 s, p = 0.007, respectively). The magnitude of ST segment depression was also less with enalapril than with placebo (mean 1.1 +/- 0.4 vs. 1.5 +/- 0.2 mm, p = 0.004). Heart rate and blood pressure at peak exercise and at 1 mm of ST depression were not significantly different during placebo and enalapril treatment. CONCLUSIONS. Angiotensin-converting enzyme inhibition lessens exercise-induced ischemia in patients with syndrome X and microvascular angina, probably by a direct modulation of coronary microvascular tone, which results in an increased myocardial oxygen supply.


This article has been cited by other articles:


Home page
CirculationHome page
G. A. Lanza and F. Crea
Primary Coronary Microvascular Dysfunction: Clinical Presentation, Pathophysiology, and Management
Circulation, June 1, 2010; 121(21): 2317 - 2325.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. O. Cannon III
Microvascular Angina and the Continuing Dilemma of Chest Pain With Normal Coronary Angiograms
J. Am. Coll. Cardiol., September 1, 2009; 54(10): 877 - 885.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. Phan, C. Shufelt, and C. N. B. Merz
Persistent Chest Pain and No Obstructive Coronary Artery Disease
JAMA, April 8, 2009; 301(14): 1468 - 1474.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S. J Russell, E. M Di Stefano, M. T Naffati, O. Brown, and S. Saltissi
The effects of the angiotensin II receptor (type I) antagonist irbesartan in patients with cardiac syndrome X
Heart, February 1, 2007; 93(2): 253 - 254.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
N. Danchin, M. Cucherat, C. Thuillez, E. Durand, Z. Kadri, and P. G. Steg
Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction: An Overview of Long-term Randomized Controlled Trials.
Arch Intern Med, April 10, 2006; 166(7): 787 - 796.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. J. Pepine, J.-L. Rouleau, K. Annis, A. Ducharme, P. Ma, J. Lenis, R. Davies, U. Thadani, B. Chaitman, H. E. Haber, et al.
Effects of angiotensin-converting enzyme inhibition on transient ischemia: The quinapril anti-ischemia and symptoms of angina reduction (QUASAR) trial
J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2049 - 2059.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. C. Kaski and L. F. Valenzuela Garcia
Therapeutic options for the management ofpatients with cardiac syndrome X
Eur. Heart J., February 2, 2001; 22(4): 283 - 293.
[PDF]


Home page
ANGIOLOGYHome page
N.-W. Hsu, J.-W. Chen, S.-L. Jen, B. I.-T. Kuo, W.-L. Lee, G.-Y. Mar, S.-J. Lin, S.-P. Wang, M.-S. Chang, and J.-W. Chen
Differentiating Syndrome X from Coronary Artery Disease by Treadmill Exercise Test in Patients with Chest Pain and Exercise-Induced Myocardial Ischemia
Angiology, January 1, 1998; 49(1): 13 - 24.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement